What is the primary driver of Abbott's improved financial performance in Q1 2002 compared to Q1 2001?

The primary driver is a significant increase in net sales, which rose 17.7% year-over-year to $4.19 billion. This growth was bolstered by strong performance in the Pharmaceutical and International segments, largely a result of the acquisition of BASF's pharmaceutical business in March 2001. This sales growth directly translated into a substantial swing from a net loss in the prior year to a healthy net profit in the current quarter.

Are there any significant legal or regulatory issues that investors should be aware of?

Yes, Abbott is involved in several ongoing legal and regulatory matters. These include antitrust suits related to pharmaceutical pricing, lawsuits concerning the sales of Hytrin, and investigations/lawsuits surrounding TAP Pharmaceutical Products Inc.'s marketing of Lupron. Additionally, Abbott is working to comply with a U.S. Food and Drug Administration (FDA) consent decree for its diagnostics manufacturing operations and is awaiting the FDA's determination on compliance. While management believes these matters will not materially adversely affect the company's financial position, they represent areas of potential risk.

What is the impact of the BASF acquisition on the financial results?

The acquisition of BASF's pharmaceutical business in March 2001 significantly impacted the Q1 2002 results. It drove a substantial portion of the year-over-year increase in net sales, particularly in the Pharmaceutical and International segments. However, it also contributed to increased operating expenses, such as selling, general, and administrative expenses, and higher amortization of intangibles, which are reflected in the financial statements.

What strategic acquisitions or divestitures were highlighted in this report?

The report highlights Abbott's agreement to acquire the cardiovascular stent business of Biocompatibles International plc for approximately $235 million, expected to close in Q2 2002. Additionally, Abbott sold its U.S. Selsun Blue product rights in Q1 2002. The significant acquisition of BASF's pharmaceutical business in March 2001 continues to have a substantial impact on current results.

ABT 10-Q Quarterly Report Q1 FY2002 — Revenue, Net Income, EPS

Summary

Abbott Laboratories reported a significant rebound in the first quarter of 2002, with net earnings of $854.3 million, a substantial improvement from a net loss of $223.6 million in the same period last year. This turnaround is largely driven by a substantial increase in net sales, which grew 17.7% year-over-year to $4.19 billion. The growth was fueled by strong performance in the Pharmaceutical and International segments, boosted by the prior year's acquisition of BASF's pharmaceutical business. Diluted earnings per share (EPS) also swung from a loss of $0.14 to earnings of $0.54, signaling a positive operational trajectory. While the company's financial performance has improved, investors should note ongoing legal proceedings and regulatory matters, particularly concerning the TAP Pharmaceutical Products Inc. joint venture and FDA compliance for diagnostics manufacturing. The company also announced an agreement to acquire Biocompatibles' cardiovascular stent business for $235 million, indicating continued strategic investment. Abbott's solid operating cash flow and strong credit ratings provide a stable financial footing.

Key Highlights

1Net earnings surged to $854.3 million from a net loss of $223.6 million in the prior year's quarter.
2Net sales increased by 17.7% to $4.19 billion, driven by strong Pharmaceutical and International segment growth.
3Diluted earnings per share improved to $0.54 from a loss of $0.14 in the first quarter of 2001.
4Gross profit margin improved to 54.7% from 53.8%, attributed to favorable product mix.
5Research and development expenses increased by 12.1%, with a continued focus on pharmaceuticals.
6The company announced an agreement to acquire Biocompatibles' cardiovascular stent business for approximately $235 million.
7Abbott is addressing ongoing legal and regulatory matters, including FDA compliance for diagnostics and the TAP Pharmaceutical Products Inc. joint venture.

ABBOTT LABORATORIES Quarterly Report for Q1 Ended Mar 31, 2002

Summary

Key Highlights

Frequently Asked Questions